Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

MyD88 L265P Mutation-Specific TCR Gene Therapy for Treatment of B-Cell Lymphoma and Leukemia

Özcan Çinar, BSc,MSc, Peter Michael Kloetzel, Caroline Anna Peuker, Ulrich Keller, Antonio Pezzutto, Antonia Busse

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-142880

Published: 2020

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

Journal Articles

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Rüdiger Hehlmann, MD, Michael Lauseker, PhD, Susanne Saussele, MD, Markus Pfirrmann, Stefan W. Krause, MD, Hans-Jochem Kolb, MD, Andreas Neubauer, MD, Dieter K. Hossfeld, Christoph Nerl, MD, Alois Gratwohl, MD, Gabriela M. Baerlocher, Dominik Heim, MD, Tim Henrik Bruemmendorf, Alice Fabarius, PhD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD PhD, Martin C. Müller, MD, Sabine Jeromin, PhD, Ulrike Proetel, PhD, Katharina Kohlbrenner, PhD, Astghik Voskanyan, PhD, Sébastien Rinaldetti, Wolfgang Seifarth, PhD, Birgit Spiess, Leopold Balleisen, MD, Maria E Goebeler, MD, Mathias Hänel, MD, Anthony D. Ho, MD, J Dengler, C Falge, Lothar Kanz, MD, Claus-Henning Köhne, MD, PhD, Andreas Burchert, MD, Michael Kneba, MD PhD, Frank Stegelmann, MD, C Köhne, Hans-Walter Lindemann, C Waller, Michael Pfreundschuh, MD, Karsten Spiekermann, Wolfgang E Berdel, MD, L Müller, Matthias Edinger, MD, Jiri Mayer, Prof, MD SCs, Dietrich W Beelen, MD PhD, Martin Bentz, MD, Hartmut Link, MDPhD, Bernd Hertenstein, MD, R Fuchs, Martin Wernli, MD, F Schlegel, Rudolph Schlag, M de Wit, Lorenz Trümper, MD, H Hebarth, M Hahn, Jörg Thomalla, MD, Christof Scheid, MD, Philippe Schafhausen, MD, Walter Verbeek, MD, Michael J. Eckart, MD, Winfried Gassmann, MD PhD, Antonio Pezzutto, MD, Michael Schenk, Peter Brossart, MD, Thomas Geer, MD, Stephan Bildat, E Schäfer, Andreas Hochhaus, MD, Joerg Hasford

Blood (2017) 130 (Supplement 1): 897.

https://doi.org/10.1182/blood.V130.Suppl_1.897.897

Published: 2017

Journal Articles

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: The Maximum Tolerated Dose Selection and the Proof of Concept Final Results

Blood (2017) 130 (Supplement 1): 253.

https://doi.org/10.1182/blood.V130.Suppl_1.253.253

Published: 2017

Journal Articles

Prognostic Impact of Distinct Combinations of Molecular Mutations in AML Patients. Results of Two-Center International Cooperation Study

Olga Blau, MD PhD, Irina Martynkevich, MD PhD, Franziska Behrenbeck, Claudia D. Baldus, MD, Ekaterina Motiko, Sergei Voloshin, MD PhD, Antonio Pezzutto, MD PhD, Bernd Dorken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2017) 130 (Supplement 1): 5111.

https://doi.org/10.1182/blood.V130.Suppl_1.5111.5111

Published: 2017

Journal Articles

A Long-Term Safety and Efficacy Study of Givinostat in Patients with Polycythemia Vera: The First 4 Years of Treatment

Guido Finazzi, MD, Alessandra Iurlo, MD PhD, Bruno Martino, Giuseppe Carli, MD, Attilio Guarini, MD, Richard Noble, MD, Alessandro M. Vannucchi, Nikolas von Bubnoff, MD, Marianna De Muro, MD, Paolo Di Bartolomeo, MD, Mary Frances McMullin, MB,Bch BAO, MD FRCPath, Vincenzo Martinelli, MD, Antonio Pezzutto, MD PhD, Vittorio Rosti, MD, Giorgina Specchia, MD, Paolo Bettica, MD PhD, Sara Manzoni, DHSC, BSc, Silvia DI Tollo, DHSC, BSc, Alessandro Rambaldi, MD Prof

Blood (2017) 130 (Supplement 1): 1648.

https://doi.org/10.1182/blood.V130.Suppl_1.1648.1648

Published: 2017

Journal Articles

90 Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Kristina Lerch, Corinna Leng, Antonello Pinto, Werner Linkesch, Heinz Sill, Ola Linden, Andreas Viardot, Ulrich Keller, Georg Hess, MD, Secondo Lastoria, Ferdinando Frigeri, Nicole Neik, Christiane Pott, Christian W. Scholz, Antonio Pezzutto, MD PhD

Blood (2016) 128 (22): 1806.

https://doi.org/10.1182/blood.V128.22.1806.1806

Published: 2016

Journal Articles

DNMT3A Mutations in AML Patients: Prognostic Impact and Comparative Analysis of Mutations Burden in Diagnostic Samples, after Standard Therapy, and after Allogeneic Stem Cell Transplantation

Olga Blau, MD PhD, Franziska Behrenbeck, Nikola Suckert, Lars R. Fransecky, MD, Claudia D. Baldus, MD, Renate Arnold, MD PhD, Antonio Pezzutto, MD PhD, Bernd Dörken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2016) 128 (22): 2891.

https://doi.org/10.1182/blood.V128.22.2891.2891

Published: 2016

Journal Articles

SIRT3 Modulates Mitochondrial Stress Response in Bone Marrow Mesenchymal Stromal Cells of Multiple Myeloma Patients

Rimma Berenstein, Igor Wolfgang Blau, MD PhD, Axel Nogai, MD, Marlies Waechter, Martin Schmidt-Hieber, MD PhD, Antonio Pezzutto, MD PhD, Bernd Doerken, MD PhD, Olga Blau, MD PhD

Blood (2015) 126 (23): 5325.

https://doi.org/10.1182/blood.V126.23.5325.5325

Published: 2015

Journal Articles

Quantitative Detection of DNMT3A R882H Mutation in Course of Treatment of Acute Myeloid Leukemia Patients

Olga Blau, MD PhD, Rimma Berenstein, Claudia Baldus, MD PhD, Nikola Suckert, Kathrin Rieger, MD, Axel Nogai, MD, Antonio Pezzutto, MD PhD, Bernd Doerken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2015) 126 (23): 4970.

https://doi.org/10.1182/blood.V126.23.4970.4970

Published: 2015

Journal Articles

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV

Blood (2015) 126 (1): 42–49.

https://doi.org/10.1182/blood-2015-01-617993

Published: 2015

Includes: Supplemental data

Journal Articles

Multiple Myeloma Cells Induce Mitochondrial Stress Response in Bone Marrow Mesenchymal Stromal Cells

Rimma Berenstein, Olga Blau, MD PhD, Axel Nogai, MD, Marlies Wächter, Martin Schmidt-Hieber, MD, Antonio Pezzutto, MD PhD, Bernd Dörken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2014) 124 (21): 3357.

https://doi.org/10.1182/blood.V124.21.3357.3357

Published: 2014

Journal Articles

Cyclin D1 C.870G>a Polymorphism in Patients with Multiple Myeloma after Allogeneic Stem Cells Transplantation

Olga Blau, MD PhD, Ekaterina Slonova, Rimma Berenstein, Axel Nogai, MD, Kathrin Rieger, MD, Antonio Pezzutto, MD PhD, Bernd Dörken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2014) 124 (21): 2576.

https://doi.org/10.1182/blood.V124.21.2576.2576

Published: 2014

Journal Articles

Flow Cytometry-Based Maturity Score As a Novel Prognostic Parameter in AML

Anne Flörcken, MD, Schneider Tanja, MD, Anju Singh, MD, Seval Türkmen, MD, Burmeister Thomas, MD PhD, Joannis Anagnostopoulos, MD PhD, Antonio Pezzutto, MD PhD, Bernd Dörken, MD PhD, Jörg Westermann, MD PhD

Blood (2014) 124 (21): 1006.

https://doi.org/10.1182/blood.V124.21.1006.1006

Published: 2014

Journal Articles

Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial

Simone Ferrero, Alessandro Pastore, Roswitha Forstpointner, M.D., Christian W. Scholz, Antonio Pezzutto, Lothar Bergmann, Lorenz Truemper, Juergen Finke, Ulrich Keller, Marco Ladetto, Wolfgang Hiddemann, M.D., Oliver Weigert, Michael Unterhalt, Martin Dreyling

Blood (2013) 122 (21): 4384.

https://doi.org/10.1182/blood.V122.21.4384.4384

Published: 2013

Journal Articles

Aberrant Expression Of miRNA and mRNA Of Cell Cycle and Adhesion-Related Genes In Bone Marrow Stroma Cells Derived From Patients With Multiple Myeloma

Rimma Berenstein, Blau Igor Wolfgang, MD, PhD, Axel Nogai, MD, Marlies Wächter, Antonio Pezzutto, MD, PhD, Bernd Dörken, MD, PhD, Olga Blau, MD, PhD

Blood (2013) 122 (21): 3149.

https://doi.org/10.1182/blood.V122.21.3149.3149

Published: 2013

Journal Articles

DNMT3A Mutations In AML: Incidence, Prognostic Influence and Association With Other Molecular Markers

Igor Wolfgang Blau, MD, PhD, Rimma Berenstein, Claudia D. Baldus, MD, PhD, Sophie Schlabitz, Asiye Kar, Ruhiye Cay, Annette Sindram, Claudia Seide, Antonio Pezzutto, Bernd Dörken, MD, PhD, Olga Blau, MD, PhD

Blood (2013) 122 (21): 2627.

https://doi.org/10.1182/blood.V122.21.2627.2627

Published: 2013

Journal Articles

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Blood (2012) 120 (21): 57.

https://doi.org/10.1182/blood.V120.21.57.57

Published: 2012

Journal Articles

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

Blood (2011) 118 (21): 4110.

https://doi.org/10.1182/blood.V118.21.4110.4110

Published: 2011

Journal Articles

90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma. First Results from an International Phase II Clinical Trial

Christian W. Scholz, MD, Antonello Pinto, MD, Werner Linkesch, MD, Ola Linden, MD, Andreas Viardot, MD, Ulrich Keller, MD, Georg Hess, MD, Kristina Lerch, MD, Ferdinando Frigeri, MD, Manuela Arcamone, MD, Bernd Frericks, MD, Christiane Pott, MD, Antonio Pezzutto

Blood (2010) 116 (21): 593.

https://doi.org/10.1182/blood.V116.21.593.593

Published: 2010

NARROW

MyD88 L265P Mutation-Specific TCR Gene Therapy for Treatment of B-Cell Lymphoma and Leukemia

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: The Maximum Tolerated Dose Selection and the Proof of Concept Final Results

Prognostic Impact of Distinct Combinations of Molecular Mutations in AML Patients. Results of Two-Center International Cooperation Study

A Long-Term Safety and Efficacy Study of Givinostat in Patients with Polycythemia Vera: The First 4 Years of Treatment

90 Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

DNMT3A Mutations in AML Patients: Prognostic Impact and Comparative Analysis of Mutations Burden in Diagnostic Samples, after Standard Therapy, and after Allogeneic Stem Cell Transplantation

SIRT3 Modulates Mitochondrial Stress Response in Bone Marrow Mesenchymal Stromal Cells of Multiple Myeloma Patients

Quantitative Detection of DNMT3A R882H Mutation in Course of Treatment of Acute Myeloid Leukemia Patients

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV

Multiple Myeloma Cells Induce Mitochondrial Stress Response in Bone Marrow Mesenchymal Stromal Cells

Cyclin D1 C.870G>a Polymorphism in Patients with Multiple Myeloma after Allogeneic Stem Cells Transplantation

Flow Cytometry-Based Maturity Score As a Novel Prognostic Parameter in AML

Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial

Aberrant Expression Of miRNA and mRNA Of Cell Cycle and Adhesion-Related Genes In Bone Marrow Stroma Cells Derived From Patients With Multiple Myeloma

DNMT3A Mutations In AML: Incidence, Prognostic Influence and Association With Other Molecular Markers

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma. First Results from an International Phase II Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only